Regulus, AstraZeneca deal

Regulus disclosed in its 2013 earnings that it and partner AstraZeneca have selected microRNA-103 (miR-103) and miR-107 as targets

Read the full 198 word article

How to gain access

Continue reading with a
two-week free trial.